Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer

Abstract

Background Triple-negative breast cancer (TNBC) constitutes 10–20% of breast cancers and is challenging to treat due to a lack of effective targeted therapies. Previous studies in TNBC cell lines showed in vitro growth inhibition when JQ1 or GSK2801 were administered alone, and enhanced activity when co-administered. Given their respective mechanisms of actions, we hypothesized the combinatorial effect could be due to the target genes affected. Hence the target genes were characterized for their expression in the TNBC cell lines to prove the combinatorial effect of JQ1 and GSK2801. Methods RNASeq data sets of TNBC cell lines (MDA-MB-231, HCC-1806 and SUM-159) were analyzed to identify the differentially expressed genes in single and combined treatments. The topmost downregulated genes were characterized for their downregulated expression in the TNBC cell lines treated with JQ1 and GSK2801 under different dose concentrations and combinations. The optimal lethal doses were determined by cytotoxicity assays. The inhibitory activity of the drugs was further characterized by molecular modelling studies. Results Global expression profiling of TNBC cell lines using RNASeq revealed different expression patterns when JQ1 and GSK2801 were co-administered. Functional enrichment analyses identified several metabolic pathways (i.e., systemic lupus erythematosus, PI3K-Akt, TNF, JAK-STAT, IL-17, MAPK, Rap1 and signaling pathways) enriched with upregulated and downregulated genes when combined JQ1 and GSK2801 treatment was administered. RNASeq identified downregulation of PTPRC, MUC19, RNA5-8S5, KCNB1, RMRP, KISS1 and TAGLN (validated by RT-qPCR) and upregulation of GPR146, SCARA5, HIST2H4A, CDRT4, AQP3, MSH5-SAPCD1, SENP3-EIF4A1, CTAGE4 and RNASEK-C17orf49 when cells received both drugs. In addition to differential gene regulation, molecular modelling predicted binding of JQ1 and GSK2801 with PTPRC, MUC19, KCNB1, TAGLN and KISS1 proteins, adding another mechanism by which JQ1 and GSK2801 could elicit changes in metabolism and proliferation. Conclusion JQ1-GSK2801 synergistically inhibits proliferation and results in selective gene regulation. Besides suggesting that combinatorial use could be useful therapeutics for the treatment of TNBC, the findings provide a glimpse into potential mechanisms of action for this combination therapy approach.

GSK2801 Reverses Paclitaxel Resistance in Anaplastic Thyroid Cancer Cell Lines through MYCN Downregulation

“…However, high expression levels of BAZ2B have been associated with poor outcome in pediatric B-cell acute lymphoblastic leukemia (B-ALL) [ 23 ]. In the last few years, small molecule bromodomain inhibitors (BDIs) have increased in usability for their effective anticancer activity and have emerged as a promising class of anticancer drugs [ 24 ]. Chen et al developed a novel inhibitor of BDs from a nonselective micromolar BAZ/BET inhibitor.…”

“…GSK2801 shows high selectivity for BAZ2A and BAZ2B, and also binds with lower affinity to BRD9 [ 25 ]. The antiproliferative effect of this inhibitor in synergy with BET inhibitors has already been tested in a triple negative breast cancer cell line [ 24 , 26 ]. Furthermore, through using the ChIP-seq approach, it was recently discovered that GSK2801 significantly disrupts chromatin binding of flag-tagged BAZ2A or BAZ2B in mouse liver H2.35 cells [ 27 ].…”

Whole genome association testing in 333,100 individuals across three biobanks identifies rare non-coding single variant and genomic aggregate associations with height

“…There is extensive literature on the genes that MIR195 and MIR497 bind and affect expression of, while there is little previous literature referencing C17orf49 , except for a small number of studies of cancer phenotypes 26 . MIR497 and MIR195 expression have been associated with a range of genes that influence cancer 27 , and both have been implicated in quiescence of skeletal muscle cells 28 .…”

Transcriptomic insights into adenoid cystic carcinoma via RNA sequencing

“…For patients with colorectal cancer, a high level of TVP23C in plasma indicates a longer survival period (Holm et al, 2019). CDRT4 is upregulated in breast cancer cells (Yellapu et al, 2022). However, research on TVP23C-CDRT4 gene fusion is very rare.…”